Morten Grunnet

Part of Novartis AG, Novartis, Inc. is a company based in San Francisco.

JSB-Partners LP offers specialized investment banking and advisory services to biotechnology and pharmaceutical companies. Its services include product partnerships, mergers and acquisitions, private placements and public underwritings. The company was founded by Wolfgang Rudolph Ralph Stoiber in 1999 and is headquartered in Boston, MA.

NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC.

Mellitus LLC develops vitro diagnostic tests for the measurement of Glycated CD59 (GCD59). Its vitro diagnostic test is also used for the stratification of complications risk and as a clinical trial test for pharmaceutical development. The company was founded by Jose Alberto Halperin, Joyce A. Lonergan and Michael Chorev in 2011 and is headquartered in Boston, MA.

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

N.V. Organon engages in the development, manufacture, and sale of prescription medicines. It offers products for cardiovascular diseases, fertility, gynecology, anesthesia, respiratory, consumer health care, neuroscience as well as immunology, animal health, and oncology. Its products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. The company was founded in 1923 and is headquartered in Oss, the Netherlands.

Akzo Nobel, Inc. provides decorative paints, performance coatings and specialty chemicals. Its products include catalysts, polymers, surfactants, and functional, pulp and paper chemicals. The firm's brands include Dulux, Sikkens and Eka. The company was founded in 1982 and is headquartered in Chicago, IL.

Pacira Pharmaceuticals, Inc. develops and manufactures injectable and sustained release therapeutic products. It focuses on clinical and commercial development activities by understanding the needs of the acute care market. The company was founded in March 2007 and is headquartered in San Diego, CA.

Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell.

Warren Pharmaceuticals, Inc. develops tissue-protective technologies. The company was founded by Anthony Cerami and Michael Brines on May 17, 2001 and is headquartered in Tarrytown, NY.

Broadview Ventures, Inc. (Broadview Ventures) is a venture capital firm founded in 2008. The firm is headquartered in Boston, Massachusetts.

Merck Serono Ltd. provides research and development services and manufactures medicinal drugs. The company is headquartered in Middlesex, the United Kingdom.

Van Leeuwen Buizen Groep BV engages in the manufacture and distribution of steel pipes, and pipe and tube applications. Its product portfolio includes round tubes, valves, hollow sections, breams, pipe components, and bar steel. The firm also offers services including material treatments, digital services, testing and inspection, technical information, logistical services, and project management. The company was founded by Piet Van Leeuwen in 1924 and is headquartered in Zwijndrecht, the Netherlands.

Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland.

Araim Pharmaceuticals, Inc. operates as a biotechnology company that develops novel treatments for devastating injuries and chronic diseases. It provides ARA 290, a novel 11 amino acid peptide that activates the body’s natural repair system through the innate repair receptor, which is present only following injury, as well as activates anti-inflammatory, tissue protective, and reparative signaling pathways. The company was founded by Anthony Cerami and Michael Brines in 2006 and is headquartered in Tarrytown, NY.

Gila Therapeutics, Inc. provides developing therapies for obesity patients. The company was founded by Sergei Zolotukhin and Andres Acosta in January 2014 and is headquartered in Excelsior, MN.

NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark.

Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.

Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium.

Nukute Oy is a Finnish company that aims to improve the diagnosis of sleep apnea. Nukute is based in Oulu, FI. The company provides a Collare system that has been evaluated for its usability and clinical performance. The company was founded by Tuukka Visuri and Toni Leinonen, with Toni Leinonen serving as the CEO since incorporation.

STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark.

Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020.

Hemab ApS develops antibodies for the treatment of rare bleeding disorders. The company is based in Copenhagen, Denmark. The Danish company was founded in 2019 by Johan Henrik Faber. Benny Sorensen has been the CEO of the company since 2020.

Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020.

Breye Therapeutics ApS is a biopharmaceutical company based in Copenhagen, Denmark. The Danish company develops novel, oral ophthalmology drugs to address the needs of millions of patients suffering from deteriorating vision due to diabetic retinopathy (DR) or age-related macular degeneration (AMD). Breye Therapeutics' lead program with Danegaptide has a clinically de-risked safety profile and potential for a short and well-accepted clinical regulatory pathway. The company aims to provide less burdensome and more effective treatments for DR and AMD patients, which are currently treated with unpopular intravitreal injections directly into the eye. The company was founded in 2019, and the CEO is Ulrik Mouritzen.

Harvest Integrated Research Organization (HIRO) is a clinical research organization that provides cross-border solutions and services to its clients, including pre-clinical strategic planning, clinical trial design, regulatory, pharmacovigilance, statistics, data management, project management, and clinical and medical monitoring services. The private company is based in Shanghai, CN, and has subsidiaries in the United States. HIRO aims to become a market-leading, integrated clinical research organization that collaborates with biotech and pharmaceutical companies to bring new products to the market, providing more effective solutions for patients worldwide. The Chinese company was founded in 2020 by Karen Chu, who has been the CEO since then.